Oxford Technology 2 VCT (GB:OXH) has released an update.
Oxford Technology 2 VCT Plc reported an increase in net asset value (NAV) per share driven by Arecor Therapeutics’ successful clinical trial results, but faced a subsequent decline in Arecor’s share price due to unexpected fundraising needs. Additionally, Scancell Holdings experienced a slight share price drop despite signing an exclusivity agreement with a major biotech firm. The company also announced it will liquidate a portion of its portfolio for operational costs, while no dividends were issued or shares traded during the quarter.
For further insights into GB:OXH stock, check out TipRanks’ Stock Analysis page.
